QUANTUM CYBER (F/K/A MAINZ BIOMED) ANNOUNCES STOCK TICKER SYMBOL CHANGE TO NASDAQ: QUCY
BERKELEY, Calif., March 13, 2026 — Mainz Biomed N.V. (NASDAQ: QUCY) doing business as Quantum Cyber, today announced, effective upon the commencement of trading on March 12, 2026 (U.S. Eastern Time), it officially changed its ticker symbol to “QUCY” on the Nasdaq Capital Market. Further the Company’s name will change to Quantum Cyber N.V. (“Quantum” […]
Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors
Company Also Announces New Name: Quantum Cyber and Change in Nasdaq Ticker symbol March 11, 2026 — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that Robert P. Liscouski has been appointed Chairman of its Board of Directors. Further, the Company announced that it […]
Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples
Mainz Biomed to Present Industry Leading Results: 100% Sensitivity and 95% Specificity BERKELEY, US – February 24, 2026 — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the renowned Digestive Disease Week (DDW) 2026 in Chicago, Illinois. At the […]
Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update
Company to Focus on Pancreatic Cancer Detection Business in the U.S., Strategic Asset Sales and Future Strategic Transaction BERKELEY, US – MAINZ, Germany – February 17, 2026 — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, announced a series of strategic transactions designed to strengthen its […]
Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting
First data on blood-based mRNA signature for pancreatic ductal adenocarcinoma (PDAC) detection and intraductal papillary mucinous neoplasms (IPMN) differentiation to be presented in San Diego BERKELEY, US – MAINZ, Germany – January 14, 2026 — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to […]
Mainz Biomed Provides Review of 2025 Highlights
Initiation of eAArly DETECT 2 – U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population in Preparation for ReconAAsense U.S. FDA Pivotal Trial Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project Study Demonstrated a Sensitivity of 100% and Specificity of 95% BERKELEY, US – […]
DoctorBox Adds Mainz Biomed’s ColoAlert® to Its Portfolio
DNA-based Colorectal Cancer Screening as a Home Test BERKELEY, US, MAINZ and BERLIN, Germany – December 02, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), molecular genetics diagnostic company specializing in the early detection of cancer,today announced that its test ColoAlert® has been added to the portfolio of DoctorBox, one of Germany’s […]
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
OncoVanguard8 is a leading service provider for innovative healthcare products for insurance companies operating in Peru, Colombia and Ecuador BERKELEY, US and MAINZ, Germany – November 18, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the signing of […]
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
BERKELEY, US and MAINZ, Germany – November 12, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in MEDICA 2025, one of the world’s leading healthcare trade shows, taking place from 17–20 November, 2025, in […]
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
BERKELEY, US and MAINZ, Germany – November 10, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) taking place from 14–15 November, […]
